Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Primary cutaneous gamma/delta-positive T-cell lymphoma is a rare, usually aggressive, subtype of cutaneous T-cell lymphoma characterized by infiltration of the epidermis, dermis or subcutaneous tissue by a clonal population of mature, gamma/delta positive cytotoxic T-cells. Typically it presents with ulcerating plaques, tumors, or subcutaneous nodules on the skin of the extremities, however, frequent involvement of mucosal and extranodal sites (such as the nasal cavity, gastrointestinal tract or lungs) is also observed. Cases associated with panniculitis may present with hemophagocytic syndrome (abrupt onset of fever, rash, cytopenia, hepatosplenomegaly and neurological compromise). Infiltration of lymph nodes, spleen and bone marrow is uncommon and resistance to multilineage chemotherapy is reported.
No clinical trials have been registered for primary cutaneous gamma/delta-positive T-cell lymphoma.
1 publication has been identified in PubMed for primary cutaneous gamma/delta-positive T-cell lymphoma. Research spans Case Report / Case Series (100%).
Erem AS (2025). [PMID: 40202044](https://pubmed.ncbi.nlm.nih.gov/40202044/). *J Cutan Pathol*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:43 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning primary cutaneous gamma/delta-positive T-cell lymphoma
Updated Aug 31, 2026
A study published on PubMed details three patients with primary cutaneous gamma-delta T-cell lymphoma, highlighting unusual clinicopathological characteristics and molecular characterization. This research may provide insights into the disease's biology and potential therapeutic targets.